14 September 2020 - Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD.

Novartis announced today that the CHMP, has approved an update to the Beovu (brolucizumab) Summary of Product Characteristics to include additional information regarding retinal vasculitis and retinal vascular occlusion. Typically, these events occurred in the presence of intra=ocular inflammation. 

This approval follows Novartis’ announcement that it would pursue worldwide label updates after a review and further characterisation of post-marketing safety events reported to Novartis.

Read Novartis press release